Abstract
In October 2009, pazopanib (Votrient; GlaxoSmithKline) — a multikinase inhibitor with targets that include vascular endothelial growth factor receptors — was approved by the US FDA for the treatment of advanced renal cell carcinoma.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment
Journal of Hematology & Oncology Open Access 15 October 2020
-
Hypertension in cancer patients treated with anti-angiogenic based regimens
Cardio-Oncology Open Access 07 December 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112–125 (2007).
Atkins, M. A. et al. Everolimus. Nature Rev. Drug Discov. 8, 535–536 (2009).
Heng, D. Y. & Bukowski, R. M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr. Cancer Drug Targets 8, 676–682 (2008).
Harris, P. A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632–4640 (2008).
Kumar, R. et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6, 2012–2021 (2007).
Food and Drug Administration. FDA labelling information. FDA website [online], (2009).
Sternberg, C. N. et al. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27, 15s A5021 (2009).
Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
Motzer, R. J. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516–2524, (2006).
Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
IMS MIDAS (IMS Health, 2009).
SG Cowen Research Team. SG Cowen Therapeutic Categories Outlook (Sep 2009).
Hauber, A., Vosser, R. & Evans, D. JP Morgan Equity Research Report (11 Sep 2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R.M.B. has received honoraria and acted as a consultant for Pfizer, Novartis and Genentech, and has acted as a consultant for GSK and Bayer.
Rights and permissions
About this article
Cite this article
Bukowski, R., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat Rev Drug Discov 9, 17–18 (2010). https://doi.org/10.1038/nrd3073
Issue Date:
DOI: https://doi.org/10.1038/nrd3073
This article is cited by
-
Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs
Journal of Cancer Research and Clinical Oncology (2023)
-
Switching on prodrugs using radiotherapy
Nature Chemistry (2021)
-
Kinase drug discovery 20 years after imatinib: progress and future directions
Nature Reviews Drug Discovery (2021)
-
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment
Journal of Hematology & Oncology (2020)
-
Targeting of proangiogenic signalling pathways in chronic inflammation
Nature Reviews Rheumatology (2016)